Erythropoietin alfa

Phase 3Biologic

NNanogen Pharmaceutical Biotechnology Joint Stock Company

Erythropoietin alfa is one of 53 biologic programs targeting Chronic Kidney Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Kidney DiseaseActive, not recruiting

Optic NeuritisActive, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Optic NeuritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

Erythropoietin alfa

NNanogen Pharmaceutical Biotechnology Joint Stock Company

Phase 3

1 3

Uloric

Takeda

Preclinical

3 4

Glucotrol

Pfizer

Preclinical

1 5

Sovaldi

Gilead

Preclinical

1 6

Flomax

Sanofi

Preclinical

—7

Miochol

BBausch Health Americas, Inc.

Preclinical

2 8

Epoetin Beta

Roche

Preclinical

5 9

Viagra

VViatris Specialty LLC

Preclinical

1 10

Januvia

ZZydus Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Study completion

NCT06919861

Clinical

Trials by Indication[1]

Infants1 trial

Darbepoetin Administration to Preterm Infants

Completed·UUniversity of New Mexico·Phase 2·NCT00334737·102 enrolled

Erythropoietin1 trial

PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).

Recruiting·IIncepta Pharmaceuticals Ltd·Phase 3·NCT07025681·56 enrolled

Chronic Kidney Disease1 trial

Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease

Completed·BBio Sidus SA·Phase 3·NCT04036253·43 enrolled

Children1 trial

Allogeneic UCB Therapy With EPO in Children With CP

Completed·MMinYoung Kim, MD, PhD·N/A·NCT01991145·92 enrolled

Optic Neuritis1 trial

Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial

Completed·UUniversity Eye Hospital, Freiburg·Phase 3·NCT01962571·108 enrolled

1 more indication

Unspecified1 trial

A Randomized, Two-treatment, Two-period, Crossover, Single-dose, Subcutaneous Injection Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine Manufactured by Nanogen Pharmaceutical Biotechnology Joint Stock Company With Eprex 4000 U Manufactured by Cilag AG in Healthy Volunteers

Not yet recruiting·NNanogen Pharmaceutical Biotechnology Joint Stock Company·Phase 1·NCT06919861·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Erythropoietin alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Erythropoietin alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Erythropoietin alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanogen Pharmaceutical Biotechnology Joint Stock Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: NNanogen Pharmaceutical Biotechnology Joint Stock Company

Erythropoietin alfa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Infants1 trial

Erythropoietin1 trial

Chronic Kidney Disease1 trial

Children1 trial

Optic Neuritis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News